news

CUPERTINO, Calif., June 20, 2019 /PRNewswire/ — DURECT Corporation (“DURECT” or the “Company”) (Nasdaq: DRRX) today announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and conditions expressed therein, the Company agreed to sell and the investors agreed to purchase 29,000,000 shares of common stock […]

CUPERTINO, Calif., June 18, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical trial, and that after reviewing safety and pharmacokinetic (PK) data from the completed cohorts, the Dose Escalation Committee (DEC) has approved commencement

CUPERTINO, Calif., May 16, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer, and Michael H. Arenberg, Chief Financial Officer, will be participating in the 20th Annual B. Riley FBR Institutional Investor Conference, taking place at the Beverly Hilton Hotel, Beverly Hills, CAMay 22-23. B. Riley FBR Institutional Investor

Live Webcast of Alcoholic Hepatitis KOL and Earnings Call on Wednesday, May 8th at 8:30 a.m. ET Call will feature discussions by KOLs Steven Flamm, M.D.. Tarek I. Hassanein, M.D., and Paul Kwo, M.D. CUPERTINO, Calif., May 7, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31,

DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial Live Webcast of AH Data Presentation and Discussions by KOLs Steven Flamm, M.D., Tarek I. Hassanein, M.D. and Paul Kwo, M.D. Tomorrow, Wednesday, May 8, 2019 at 8:30 a.m. ET CUPERTINO, Calif., May 7, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today

Call will feature discussions by KOLs Steven Flamm, M.D.. Tarek I. Hassanein, M.D., and Paul Kwo, M.D. Conference call and live webcast with slides on Wednesday, May 8th at 8:30 a.m. ET CUPERTINO, Calif., May 3, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report preliminary data from the ongoing DUR-928

CUPERTINO, Calif., April 25, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today the appointment of two new members to its board of directors.  Dr. Gail M. Farfel, Executive Vice President and Chief Development Officer of Zogenix, Inc., and Judith J. Robertson, most recently Chief Commercial Officer of Aerie Pharmaceuticals, bring to DURECT extensive product development,

CUPERTINO, Calif., April 1, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Michael Arenberg, Chief Financial Officer, will be presenting at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9 at 10:50 a.m. BST / 05.50 a.m. EDT.  The conference is being held at the JW Marriott Grosvenor House in London.  Institutional

CUPERTINO, Calif., March 27, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH.  DUR-928, the lead investigational product in the Company’s Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in chronic hepatic

CUPERTINO, Calif., March 21, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis.  DUR-928, the lead investigational product in the Company’s Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have